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Diabetes burDen in inDia : MeDical, 
social anD econoMic
Diabetes has emerged as a major health care problem in India. According to the Diabetes Atlas published 
by the International Diabetes Federation (IDF), there 
are an estimated 40 million persons with diabetes 
in India in 2007 and this number is predicted to rise 
to almost 70 million people by 2025 by which time 
every fifth diabetic subject in the world would be an 
Indian.1 Genetic predisposition combined with life style 
changes, associated with urbanization and globalization, 
contribute to this rapid rise of diabetes in India.2 
Moreover, type 2 diabetes in the Indian population 
appears to occur at least a decade earlier compared to 
Europeans.3 This means that, in the next 10 – 20 years, 
productivity of the youth of our country could be 
seriously affected.1,4 Due to these sheer numbers, the 
economic burden due to diabetes in India is among 
the highest in the world.5 The real burden of the 
disease is however due to its micro and macrovascular 
complications which lead to increased morbidity and 
mortality.6,7 It is also known that almost 50% of people 
with diabetes remain undetected and hence some may 
even present with microvascular and macrovascular 
complications at the time of diagnosis.8,9
Although sporadic studies on prevalence of diabetes 
have been available for several decades, reliable 
epidemiological data became available in India since 
the 1970’s. Published studies vary in methodologies 
adopted and sampling frames and hence comparison 
of prevalence rates is, strictly speaking, not meaningful. 
However as Table 1 shows, despite all methodological 
issues, there is little doubt that the prevalence rates 
are rising in India.10-39 The Indian Council of Medical 
Research (ICMR) study done in the 1970’s reported a 
prevalence of 2.3% in urban areas11,12 which has risen 
to 12-19 % in 2000’s. Correspondingly, in rural areas, 
prevalence rates have increased from around 1%11,12 to 
4-10%, and even 13.2% in one study.36 Thus it is clear 
that both in urban and rural India, prevalence rates of 
diabetes are rising rapidly with a rough urban-rural 
divide of 2:1 or 3:1 being maintained through the last 
2-3 decades with the exception of Kerala where rural 
prevalence rates have caught up with or even overtaken 
urban prevalence rates.38 The probable explanation for 
this phenomenon is that in Kerala, there is indeed no 
clear urban/rural demarcation and the whole of Kerala 
can now be considered to be urbanized.
Data on various complications of diabetes have 
also been published by several authors (Table 2).40-58 
However, till recently, most such data were hospital 
or clinic based and therefore subject to referral bias. 
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abstract
With an estimated 40 million people suffering from the condition, the largest in any country in the world, 
diabetes has become a major health care problem in India. Recent epidemiological studies from India point to 
the great burden due to diabetes and its micro and macrovascular complications. This is primarily because the 
status of diabetes control in India is far from ideal. Based on the available data, the mean glycated hemoglobin 
levels are around 9% which is at least 2% higher than the goal currently suggested by international bodies. 
The IMPROVE study has helped identify the barriers to good control of diabetes both among patients as well 
as physicians in today’s practice. However the recent ACCORD study points to the dangers of overaggressive 
treatment, especially in high risk in elderly patients. A balanced approach to improve awareness about 
diabetes and its control both among patients and the medical fraternity is urgent need of the hour in India. 
The associated risks of tight control in high risk groups should also be kept in mind. ©
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Moreover they had often not used standardized 
technologies (e.g. retinal photography to document 
diabetic retinopathy).
The Chennai Urban Rural Epidemiology Study 
(CURES) and the Chennai Urban Population Study 
(CUPS) provide the first population based data from 
India on virtually all complications of diabetes. 
CURES was a population-based study involving 
26,001 participants aged 20 years or above based on 
a representative population of Chennai. The overall 
prevalence of diabetic retinopathy based on four-field 
stereo colour retinal photography was 17.6%.44 The 
prevalence of overt nephropathy was 2.2% while that of 
microalbuminuria was 26.9%.51 Peripheral neuropathy 
based on biothesiometry was seen in 26.1%.57
In the CUPS study, coronary artery disease was 
seen in 21.4% of diabetic subjects, 14.9% of subjects 
with impaired glucose tolerance and in 9.1% of people 
with normal glucose tolerance.54 In the same study, 
peripheral vascular disease was present in 6.3% 
of diabetic subjects compared to 2.7% among non-
diabetic subjects.55 Diabetic subjects also had increased 
subclinical atherosclerosis as measured by intimal 
medial thickness at every age point, compared to their 
non-diabetic counterparts.58 Assuming that 40 million 
people in India have diabetes, this translates to at least 7 
million with retinopathy, 0.8 million with nephropathy, 
10.4 million with neuropathy, 8.5 million with CAD and 
2.5 million with PVD. Thus, the burden due to diabetic 
complications is very high in India due to the sheer 
number of people with diabetes. These figures are in 
fact very conservative and it is possible that in rural 
areas, the prevalence of complications is much higher 
because of poorer control of diabetes and lack of access 
to health care. 
awareness of Diabetes in inDia
Not only is there a huge number of people with 
diabetes in India but awareness levels are also low. 
CURES reported that nearly 25% of the population 
was unaware of a condition called diabetes.59 Only 
around 40% of the participants felt that the prevalence 
of diabetes was increasing and only 22.2% of the 
population and 41% of known diabetic subjects felt 
that diabetes could be prevented.59 Though the 
awareness levels increased with education, only 42.6% 
of postgraduates and professionals, which group 
included doctors and lawyers, knew that diabetes was 
table 1 : Prevalence of diabetes in urban and rural india
Year Author (Reference) Place       Prevalence (%)
   Urban Rural
1971 Tripathy et al10  Cuttack 1.2 -
1972 Ahuja et al11 Multicentre (ICMR) 2.3  1.5
1978 Gupta et al12 Multicentre 3.0 1.3
1984 Murthy et al13 Tenali 4.7 -
1986 Patel14 Bhadran 3.8 -
1988 Ramachandran et al15 Kudremukh  5.0 -
1989 Kodali et al16 Gangavathi  - 2.2
1989 Rao et al17 Eluru 1.6 -
1991 Ahuja et al18 New Delhi 6.7 -
1994 Wander et al19 Punjab - 4.6
1997 Ramachandran et al20 Chennai 11.6 -
2000 Ramankutty et al21 Kerala 12.4 2.5
2000 Zargar et al22 Kashmir - 4.0
2001 Ramachandran et al23 National Urban Diabetes Study (NUDS)  12.1 -
2001 Misra et al24 New Delhi 10.3 -
2001 Mohan et al25 Chennai (CUPS) 12.1 -
2001 Sadikot et al26 Prevalence of Diabetes in India Study (PODIS) 5.6 2.7
2003 Gupta et al27 Jaipur 8.6 -
2004 Agarwal et al28 Rajasthan - 1.8
2004 Ramachandran et al29 Chennai - 6.4
2004 Mohan et al30 Chennai (CURES) 14.3 -
2005 Basavanagowdappa et al31 Mysore - 3.8
2005 Prabhakaran et al32 Delhi 15.0 -
2006 Reddy et al33 National 10.1 -
2006 Deo et al34 Maharastra - 9.3
2006 Menon et al35 Ernakulam 19.5 -
2006 Chow et al36 Andhra - 13.2
2007 Raghupathy et al37 Vellore 3.7 2.1
2008 Mohan et al38 Multicentre (WHO – ICMR) Self reported  7.3 3.1
2008 Ramachandran39 Tamil Nadu 18.6 9.2
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preventable.  The knowledge of risk factors of diabetes 
was even lower with only 11.9% of the study subjects 
reporting obesity and physical inactivity as risk factors 
for diabetes. More alarming was the fact that even 
among known diabetic subjects, only 40.6% were 
aware that diabetes could lead to some organ damage.59 
There is another population based study which was 
done to find out the levels of awareness on diabetes in 
urban adult Indian population aged ≥ 20 years details 
regarding awareness about diabetes.60 Knowledge 
regarding causes of diabetes, its prevention and the 
methods to improve health was significantly low among 
the general population. In the total study group, 41% 
were unaware of health being affected by diabetes and 
only less than 30% knew about complications related to 
kidneys, eyes and nerves. Many persons with diabetes 
(46%) felt it was a temporary phenomenon. Among the 
diabetic subjects 92.3% had sought the help of a general 
practitioner to take treatment. Only a small proportion 
went to a specialist. 
current status of Diabetes control 
in inDia
The next challenge in India is that the quality of 
diabetes care varies considerably depending upon 
the awareness levels, expertise available, attitudes 
and perceptions amongst diabetes care providers. An 
estimate based on sales of anti-diabetic pharmaceutical 
agents shows that on an average only 10-12% of 
people with diabetes receive modern pharmacological 
treatment in India.61 In 1998, the Diabcare–Asia study 
was carried out to investigate the relationship between 
diabetes control, management and late complications 
in a subset of urban Indian diabetes population treated 
at 26 tertiary diabetes care centres.62 A total of 2,269 
patients participated in this study and it was observed 
that approximately half the patients had poor control 
(HbA1c > 2% points above upper limit of normal) and 
mean HbA1c was significantly higher (8.9 ± 2.1%) than 
the levels recommended by the American Diabetes 
Association63 and the ICMR guidelines in India.64 Over 
54% patients had diabetes related complications. The 
mean HbA1c levels and frequency of complications 
were higher in patients with longer diabetes duration. 
This study also showed that 4% of patients were on 
diet therapy, 53.9% were receiving oral anti-diabetic 
agents (OHA’s), 22% were receiving insulin and 19.8% a 
combination of insulin and OHA’s. This study concluded 
that with increasing duration of diabetes, glycemic 
control deteriorates leading to late complications. It also 
confirmed that diabetes care in India leaves much to be 
desired and suggested the need for efforts to increase 
awareness amongst health professionals to improve 
diabetes care in India.65
table 2 : Population and clinical based studies on prevalence of diabetes complications in india
Author (Reference) Type of the study City  Prevalence
retinoPatHY
Rema et al, 199640 Clinical based Chennai 34.1%
Dandona et al, 199941 Population based Hyderabad 22.6%
Ramachandran et al, 1999 (42) Clinical based Chennai 23.7%
Rema et al, 2000 (8)  Clinic based Chennai  7.3%
Narendran et al, 2002 (43) Population based Palakkad 26.8
Rema et al, 2005 (44) Population based Chennai 17.6%
nePHroPatHY
John et al, 1991 (45) Clinic based  Vellore  Microalbuminuria: 19.7%
   Diabetic nephropathy: 8.9%
Gupta et al, 1991 (46) Clinical based New Delhi Microalbuminuria: 26.6%
Yajnik et al, 1992 (47) Clinic based Pune Microalbuminuria: 23.0%
Vijay et al, 1994 (48) Clinical based Chennai Proteinuria: 18.7%
Mohan et al, 2000 (49) Clinical based Chennai Macroproteinuria with retinopathy: 6.9% 
Varghese et al, 2001 (50) Clinical based Chennai Microalbuminuria: 36.3%
Unnikrishnan et al, 2006 (51) Population based Chennai Microalbuminuria : 26.9%
   Overt nephropathy with diabetic
   retinopathy : 2.2%
coronarY arterY Disease
Mohan et al, 1995 (52) Clinical based Chennai 17.8%
Ramachandran et al, 1999 (53) Clinical based Chennai 11.4%
Mohan et al, 2001 (54) Population based Chennai 21.4%
PeriPHeral Vascular Disease
Premalatha et al, 2000 (55)  Population based Chennai 6.3%
PeriPHeral neuroPatHY
Ramachandran et al, 1999 (42) Clinical based Chennai 27.5%
Ashok et al, 2002 (56) Clinical based Chennai 19.1%
Pradeepa et al (57) Population based Chennai 26.10%
carotiD atHerosclerosis 
Mohan et al, 2001 (58) Population based Chennai 20%
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tHe iMProVetM control inDia (ici) 
stuDY
The IMPROVE Control India (ICI) study involved 
451 clinicians and was carried out in the 8 metropolitan 
cities of India. Face to face interviewing using a mix of 
both qualitative and quantitative techniques was used 
in the study. The main objectives of the study were 
to shed light on the doctors and patients’ knowledge, 
expectations and attitudes with regards to glucose 
control, and to understand the barriers to achieving 
good glucose control among patients and health 
professionals.
This study showed that though insulin therapy is 
accepted as one of the most effective and dependable 
treatment option in management of diabetes, there are 
several barriers to its usage among type 2 diabetic cases 
particularly the acceptance of insulin therapy. There 
were many other barriers identified in terms of regular 
monitoring of diabetes status and lack of standardization 
in laboratory techniques. Surprisingly, the majority of 
these barriers involved the treating doctors as well.
From the doctor’s perspective, the ICI study observed 
no consensus on targets and guidelines amongst the 
treating doctors, e.g., lack of consensus on parameters 
to be measured [fasting or post prandial plasma glucose 
(PPG) or glycated haemoglobin (HbA1c)] or on the 
ideal target values of HbA1c. Various studies from 
India65 have confirmed the association of HbA1c with 
prevalent diabetic complications44,51,57 as well as with 
cardiovascular disease.65 In accordance with current 
guidelines in the management of diabetes in the ICI 
study also, most doctors agreed that HbA1c testing is 
crucial. However, as shown in Figure 1 the advice for 
HbA1c testing was given in only in 79% as against that 
of FPG & PPG in 97% & 96% of patients respectively. 
Although HbA1c was considered as an important 
parameter in diabetes management, the emphasis 
on this test while making the patient understand the 
importance of various tests was relatively very low 
(Fig. 1). When it came to patient’s perception, in 19% 
of cases HbA1c was felt to be a routinely advised 
test (Fig. 2). Moreover only 1/3rd of the patients were 
aware of the HbA1c test (Fig. 2). Many doctors felt 
that standardization of HbA1c in laboratories is not 
reliable and therefore preferred only FPG and PPG 
measurements. Even when HbA1c tests were requested, 
they were done only once or twice a year.
Fig. 1 : Routine tests advised - Doctors (IMPROVETM Control India Study)
Fig. 2 : Routine tests advised – patient’s perspective (IMPROVETM Control India Study)
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Moreover, even among patients whose HbA1c 
values were measured, most (53%) were not given 
glycemic targets as the study also reported relaxation 
of targets as duration of diabetes increased. Difficulty 
in long-term maintenance of HbA1c targets were 
recognized by majority of doctors. This might be one of 
the contributing factors towards lack of motivation to 
achieve good glycemic control by the patients. 
“clinical inertia” in Diabetes – 
failure to acHieVe tigHt control
Failure of initiation of or intensification of therapy, 
when indicated, is termed “clinical inertia”. Though we 
have well-defined management goals, effective therapies 
and practice guidelines, there is often a failure to take 
appropriate action despite recognition of the problem. 
This is a common problem in management of patients 
with asymptomatic chronic illnesses. Use of “soft” 
reasons to avoid intensification of therapy and lack of 
education, training and practice organization aimed at 
achieving therapeutic goals are the common reasons for 
clinical inertia. Data from the United States suggest that 
of the 65% of the patients diagnosed with diabetes, only 
73% are prescribed pharmacologic therapy and only 33% 
of those thus treated achieve a hemoglobin A1C value 
of less then 7% by the ADA goal.66
Clinical inertia in achieving glycemic targets in Indian 
diabetic subjects could be expected to be even more 
due to the low rates of awareness of diabetes and its 
complications in India resulting in poor glycemic control 
seen in Indians with diabetes. Moreover other factors 
like poverty, lack of accessibility to health services 
and inadequate follow-up are additional factors in 
developing countries like India.
Consequently insulin is delayed until it is absolutely 
necessary. Most patients are initiated on insulin after 
a course of multiple oral anti-diabetic drugs. Insulin 
therapy is initiated only when the HbA1c levels had 
deteriorated further to around 9%. Doctors often delay 
insulin therapy worrying that the daily injections, 
modification of lifestyle due to insulin and dependence 
on insulin for life and that patients may feel that insulin 
therapy indicates the last stage of diabetes. However, 
patients who had moved on to insulin seemed to have a 
more positive approach towards his/her treatment due 
to improve in quality of life and better control despite 
the issues outlined above.
The ICI study also tried to evaluate the patient’s 
attitudes towards glucose control. Most patients were 
under the impression that they were in control of their 
diabetes despite lack of knowledge of their blood sugar 
levels. The average patient’s perception of being in good 
control of diabetes was the fact that he/she complied 
with medication, diet, exercise plan and that they did 
not feel any untoward symptoms. Too few of them 
stated or knew target blood glucose or HbA1c values 
as a measure of control of their diabetes.
tHe accorD trial – tHe otHer siDe 
of tigHt control of Diabetes
One of the primary objectives of the randomized 
multicentric trial Action to Control Cardiovascular 
Risk in Diabetes (ACCORD), was to determine whether 
intensive lowering of blood sugar levels would reduce 
the risk of fatal and non-fatal cardiovascular events, 
specifically in type 2 diabetic subjects, who are at a 
high risk of developing a cardiovascular event. It was 
conducted in the USA and in Canada and included 
adults in the 40-82 years age group who had, in addition 
to diabetes, two or more other risk factors for heart 
disease or had been diagnosed with heart disease prior 
to the study. The participants had been having diabetes 
for 10 years on an average, at the time of enrollment. 
Of the 10,251 participants in the study, 5,128 were 
randomized to the intensive glycemic control group 
(target HbA1c < 6.0%) and 5123 to the standard glycemic 
control group (target HbA1c between 7.0 and 7.9%).67 
Unfortunately, this study showed that out of the total 
deaths reported from among the study participants 
after having been followed up for nearly 4 years, 257 
were in the intensively treated group and 203 in the 
standard treatment group.68 Following this, the intensive 
treatment given to participants randomized to that 
group was stopped 18 months ahead of the protocol time 
and the patients randomized to the intensive glycemic 
control group also started receiving the same treatment 
as the standard glycemic control group.67 However, 
the deaths were due to different causes like surgical 
complications, sepsis and strokes, many were heart 
attacks and no specific cause for the increase in deaths 
in the intensive treatment group was identifiable and 
no medication was deemed responsible. A hypothesis 
proposed was that though atherosclerosis was more 
in diabetic subjects than in others, the extra sugar in 
the plaques stabilized them. Hence, when diabetes 
was over aggressively controlled (target HbA1c < 
7.0%), the plaques are believed to lose their stability 
with increased likelihood of their rupture. The little 
or no relationship established between HbA1c and 
cardiovascular problems in type 2 diabetes in studies 
including the 20-year United Kingdom Prospective 
Diabetes Study (UKPDS), was quoted as support for this 
hypothesis. Another hypothesis was that hypoglycemic 
episodes associated with insulin treatment could 
cause tachycardia and have untoward effects on the 
cardiovascular system.68
The ACCORD trial is a warning to clinicians of the 
consequences of overaggressive treatment of type 2 
diabetes especially in high risk groups such as the 
elderly. It highlights that the treatment goals should be 
individualized according to the patient’s health profile 
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and not all diabetic subjects should be aggressively 
treated. Further, it establishes the need of achieving 
a balance between the benefits of intensive glycemic 
control and the disadvantages of standard glycemic 
control.
conclusions
Considering the enormous burden due to diabetes in 
India, it is important to realize the cost-effective measures 
of diabetes care like early screening, tight metabolic 
control, monitoring of risk factors and assessing of 
organ damage. The study done for economic analysis 
in diabetes care in India has also shown that the cost of 
providing routine care is only a fraction of the overall 
cost and is perhaps still manageable. However, when 
this is not available or its quality is poor, the overall 
direct and indirect costs escalate with disastrous health 
and economic consequences to the individual, his family 
and society particularly due to the onset of the micro and 
macrovascular complications of diabetes.69 Published 
data from several epidemiological, experimental human 
and animal studies as well as the data from several mega 
trials like DCCT, Kumomoto study and UKPDS have 
convincingly proved the importance of tight metabolic 
control in arresting and preventing the progression 
of target organ damage. In the last two decades there 
is better understanding of pathophysiology of type 
2 diabetes and availability of newer oral drugs for 
diabetes, newer insulin and improved delivery systems 
should translate to improve diabetes control. However 
the survey described above indicates the gaps between 
the guidelines and real life practice.36,70-72 In view of this, 
appreciation and understanding of both patient and 
physician barriers regarding proper monitoring and 
judicious use of therapeutic options including insulin 
therapy for optimizing diabetes management should be 
encouraged in order to improve control of diabetes in 
India. Result oriented organized programmes involving 
patient education, updating medical fraternity on 
various developments in the management of diabetes 
and providing them the opportunity to use and 
analyze these newer treatment options in the form of 
observational studies is required to combat the diabetes 
epidemic currently threatening to affect the lives of 
millions of people in India.
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